These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
660 related articles for article (PubMed ID: 23354017)
1. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Rodríguez-Soler M; Pérez-Carbonell L; Guarinos C; Zapater P; Castillejo A; Barberá VM; Juárez M; Bessa X; Xicola RM; Clofent J; Bujanda L; Balaguer F; Reñé JM; de-Castro L; Marín-Gabriel JC; Lanas A; Cubiella J; Nicolás-Pérez D; Brea-Fernández A; Castellví-Bel S; Alenda C; Ruiz-Ponte C; Carracedo A; Castells A; Andreu M; Llor X; Soto JL; Payá A; Jover R Gastroenterology; 2013 May; 144(5):926-932.e1; quiz e13-4. PubMed ID: 23354017 [TBL] [Abstract][Full Text] [Related]
2. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306 [TBL] [Abstract][Full Text] [Related]
3. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome. Berginc G; Bracko M; Ravnik-Glavac M; Glavac D Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325 [TBL] [Abstract][Full Text] [Related]
4. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055 [TBL] [Abstract][Full Text] [Related]
5. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M Tumori; 2014; 100(3):315-20. PubMed ID: 25076244 [TBL] [Abstract][Full Text] [Related]
6. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491 [TBL] [Abstract][Full Text] [Related]
7. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers. Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164 [TBL] [Abstract][Full Text] [Related]
8. Implication of DNA repair genes in Lynch-like syndrome. Xicola RM; Clark JR; Carroll T; Alvikas J; Marwaha P; Regan MR; Lopez-Giraldez F; Choi J; Emmadi R; Alagiozian-Angelova V; Kupfer SS; Ellis NA; Llor X Fam Cancer; 2019 Jul; 18(3):331-342. PubMed ID: 30989425 [TBL] [Abstract][Full Text] [Related]
10. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers. Kang SY; Park CK; Chang DK; Kim JW; Son HJ; Cho YB; Yun SH; Kim HC; Kwon M; Kim KM Int J Cancer; 2015 Apr; 136(7):1568-78. PubMed ID: 25110875 [TBL] [Abstract][Full Text] [Related]
13. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016 [TBL] [Abstract][Full Text] [Related]